Positive News SentimentPositive News Lucid Diagnostics Stock Price, News & Analysis (NASDAQ:LUCD) $1.54 +0.07 (+4.76%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$1.47▼$1.5450-Day Range$1.16▼$1.5452-Week Range$1.04▼$2.00Volume74,103 shsAverage Volume64,765 shsMarket Capitalization$68.79 millionP/E RatioN/ADividend YieldN/APrice Target$3.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Lucid Diagnostics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside111.0% Upside$3.25 Price TargetShort InterestHealthy1.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$5,821 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.26) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector569th out of 952 stocksSurgical & Medical Instruments Industry62nd out of 89 stocks 3.5 Analyst's Opinion Consensus RatingLucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.25, Lucid Diagnostics has a forecasted upside of 111.0% from its current price of $1.54.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.17% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 9.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUCD. Previous Next 2.7 News and Social Media Coverage News SentimentLucid Diagnostics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,821.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 4.30% of the stock of Lucid Diagnostics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($1.26) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLucid Diagnostics has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lucid Diagnostics Stock (NASDAQ:LUCD)Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Read More LUCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUCD Stock News HeadlinesNovember 16, 2023 | finance.yahoo.comLucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | msn.comLucid Diagnostics Non-GAAP EPS of -$0.22 in-line, revenue of $0.8M beats by $0.01MDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 10, 2023 | benzinga.comEarnings Preview For Lucid DiagnosticsNovember 9, 2023 | msn.comElucid closes $80m Series C for AI cardiovascular risk diagnostic toolNovember 2, 2023 | finance.yahoo.comLucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services ForumNovember 1, 2023 | finance.yahoo.comPAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023October 31, 2023 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023December 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 31, 2023 | finance.yahoo.comLucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer DetectionSeptember 21, 2023 | finance.yahoo.comPAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 11, 2023 | cnbc.comU.S. electric carmaker Lucid is exploring China entry; confirms mass market models aheadAugust 24, 2023 | finance.yahoo.comLucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee BenefitAugust 16, 2023 | finanznachrichten.dePAVmed Inc.: PAVmed Provides Business Update and Second Quarter Financial ResultsAugust 16, 2023 | finance.yahoo.comQ2 2023 Lucid Diagnostics Inc Earnings CallAugust 15, 2023 | finance.yahoo.comPAVmed Provides Business Update and Second Quarter Financial ResultsAugust 12, 2023 | businessinsider.comI drove the $180,000 Lucid Air and saw why it's one of the most impressive Tesla rivals yetJuly 31, 2023 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023July 31, 2023 | finance.yahoo.comPAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023July 29, 2023 | thestreet.comLucid Diagnostics Inc.July 19, 2023 | finance.yahoo.comPAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare CoverageJune 22, 2023 | marketwatch.com8-K: Lucid Diagnostics Inc.June 14, 2023 | finance.yahoo.comPAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLCJune 5, 2023 | finance.yahoo.comLucid Diagnostics Launches First EsoGuard® Mobile Test UnitJune 2, 2023 | finance.yahoo.comPAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding MemberMay 18, 2023 | finance.yahoo.comQ1 2023 PAVmed Inc Earnings CallMay 17, 2023 | markets.businessinsider.comWhere Lucid Diagnostics Stands With AnalystsSee More Headlines Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2022Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LUCD CUSIPN/A CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$3.25 High Stock Price Target$4.00 Low Stock Price Target$2.50 Potential Upside/Downside+111.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,170,000.00 Net Margins-4,153.13% Pretax Margin-3,784.27% Return on Equity-901.79% Return on Assets-141.57% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual Sales$380,000.00 Price / Sales181.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book2.61Miscellaneous Outstanding Shares44,670,000Free Float42,523,000Market Cap$68.79 million OptionableNot Optionable Beta1.86 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Lishan Aklog M.D. (Age 57)Chairman & CEO Dr. Sanford D. Markowitz M.D.Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor BoardDr. Joseph Willis M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardDr. Amitabh Chak M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardRichard D. YazbeckChief Technology OfficerDr. Suman M. Verma M.D.Ph.D., Chief Scientific OfficerDr. Brian J. deGuzman M.D. (Age 58)Chief Compliance Officer Mr. Michael Adam Gordon (Age 49)General Counsel & Secretary Michael ParksVice President of Investor RelationsMore ExecutivesKey CompetitorsDelcath SystemsNASDAQ:DCTHIceCure MedicalNASDAQ:ICCMPro-DexNASDAQ:PDEXCarmellNASDAQ:CTCXCytosorbentsNASDAQ:CTSOView All CompetitorsInsiders & InstitutionsLPL Financial LLCBought 14,000 shares on 11/13/2023Ownership: 0.065%Stanley LapidusSold 200 sharesTotal: $286.00 ($1.43/share)Stanley LapidusSold 3,817 sharesTotal: $5,534.65 ($1.45/share)View All Insider TransactionsView All Institutional Transactions LUCD Stock Analysis - Frequently Asked Questions Should I buy or sell Lucid Diagnostics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares. View LUCD analyst ratings or view top-rated stocks. What is Lucid Diagnostics' stock price target for 2024? 2 brokers have issued 1-year price targets for Lucid Diagnostics' stock. Their LUCD share price targets range from $2.50 to $4.00. On average, they expect the company's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 111.0% from the stock's current price. View analysts price targets for LUCD or view top-rated stocks among Wall Street analysts. How have LUCD shares performed in 2023? Lucid Diagnostics' stock was trading at $1.36 on January 1st, 2023. Since then, LUCD shares have increased by 13.2% and is now trading at $1.54. View the best growth stocks for 2023 here. When is Lucid Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our LUCD earnings forecast. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its earnings results on Monday, March, 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.12. Lucid Diagnostics had a negative trailing twelve-month return on equity of 901.79% and a negative net margin of 4,153.13%. When did Lucid Diagnostics IPO? (LUCD) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are Lucid Diagnostics' major shareholders? Lucid Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include LPL Financial LLC (0.07%). View institutional ownership trends. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:LUCD) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.